Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Quince Therapeutics, Inc. (NASDAQ:QNCX) has received a consensus rating of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $8.00.

Several analysts have issued reports on the stock. D. Boral Capital upped their price target on shares of Quince Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Quince Therapeutics in a research note on Monday, December 29th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Quince Therapeutics in a research note on Tuesday, January 6th.

Quince Therapeutics Price Performance

Shares of QNCX opened at $2.69 on Monday. Quince Therapeutics has a 1 year low of $0.72 and a 1 year high of $4.55. The stock has a 50 day simple moving average of $2.94 and a two-hundred day simple moving average of $2.13. The firm has a market cap of $149.78 million, a P/E ratio of -2.22 and a beta of 1.15.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). On average, equities analysts anticipate that Quince Therapeutics will post -1.21 earnings per share for the current year.

Hedge Funds Weigh In On Quince Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of QNCX. XTX Topco Ltd purchased a new stake in shares of Quince Therapeutics during the second quarter worth about $37,000. GSA Capital Partners LLP raised its position in Quince Therapeutics by 158.0% during the 3rd quarter. GSA Capital Partners LLP now owns 87,235 shares of the company’s stock valued at $142,000 after purchasing an additional 53,417 shares during the last quarter. Bridgeway Capital Management LLC lifted its holdings in Quince Therapeutics by 20.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock worth $212,000 after buying an additional 22,200 shares during the period. Rockefeller Capital Management L.P. bought a new stake in shares of Quince Therapeutics in the 2nd quarter worth approximately $280,000. Finally, Union Square Park Capital Management LLC grew its position in shares of Quince Therapeutics by 86.0% in the 3rd quarter. Union Square Park Capital Management LLC now owns 224,746 shares of the company’s stock worth $366,000 after buying an additional 103,889 shares during the last quarter. 30.75% of the stock is owned by institutional investors.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.